Boca Raton, FL- TheStockWizards.net is a Top Penny Stock newsletter that presents stocks that have impact news and positive technical charting indicators on the OTC BB: and Pink Sheet markets. In addition to our newsletter, TheStockWizards.net is quickly becoming the fastest growing network destination for Penny & Micro-Cap stocks. With our over 30 years combined experience; our team of research analyst pride themselves on small cap companies that are diamonds in the ruff.
At The Stock Wizards, we analyze daily market activity and provide our members with our technical outlook, winning stock picks, a weekly top ten list, and daily trading tips from the Traders Corner section of our website. We follow certain patterns and bring you break out alerts, volume spikes, breaking news, upward trends, mergers and more. We do all the research for you and send it straight to your inbox.
The Stock Wizards has just discovered an exciting Stem Cell Company trading under 5.00 dollars per share, with an initial focus on diabetes and cardiac diseases.
Proteonomix, Inc., a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy. The stem cell therapy involves introduction of healthy new stem cells to repair and replace damaged or lost cells.
PROT recently announced that they have licensed Stromal Cell Technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. Licensed from the Cohen-McNiece Foundation, this cellular technology was developed for patients who have suffered myocardial infarctions, commonly known as a heart attack.
Myocardial infarction is the interruption of blood supply to part of the heart, causing some heart cells to die. The supply of blood to the heart muscle is severely reduced or stopped. Myocardial Infarction (MI) is the leading cause of death in the United States. According to the American Heart Association, more then 1.5 million Americans suffer a myocardial infarction every year, and nearly half a million die.
A preferred embodiment of the technology is:
a) Enriching unique cells from bone marrow samples;
b) Expanding these cells using a proprietary patent-pending method; and
c) Harvesting the stromal cell product for potential therapeutic use.
Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging skin care cosmetics based on stem cell derivatives.
Proteoderm is the first company to use a matrix of proteins originally derived from non-embryonic stem cells, Matrix NC-138, to harness the anti-aging potential of stem cells in cosmeceutical products. Proteoderm does not use enzymes, collagen or growth factors which are the ingredients of other anti-aging cosmeceuticals and Proteoderm does not utilize embryonic stem cells as a source for its anti-aging skin care products.
PROT — Proteonomix, Inc.
Technical Outlook
The Stock Wizards loves the share structure of PROT. With only 4.2 million shares outstanding, the stock could really break out with any kind of volume. In addition to the share structure, TSW loves the technical setup on the chart. A breakout above the psychological $5.00 area could send this stock a lot higher. PROT is in the right sector, Stem Cells. A very interesting story indeed. This is a long-term play and TSW will be watching very closely.
To get the full list of top10 stocks for the week please click here. http://bit.ly/caFZLZ
TheStockWizards.net has not been compensated for its profile of PROT.
Forward-Looking Statement: This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
TheStockWizards.net has not been compensated for any stocks featured in this article. TheStockWizards.net is not a registered investment advisers or broker/dealer. TheStockWizards.net makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
Dana Salvo has personally traded Penny Stocks for over 15 years. He has developed trading techniques that consistently make people money. His techniques and strategies are simple but powerful. “Traders and investors tell me all the time that you cannot apply technical analysis to Penny Stocks.” To prove them wrong, I put together a team of Penny Stock experts; I like to call “The Stock Wizards” and launched TheStockWizards.net, my own Penny Stock Newsletter Site.
The Stock Wizards is a Premiere Financial Portal & Investor Relations Firm that brings a wealth of trading resources to Small Cap Investors. We analyze daily market activity and provide our members with hot stocks to watch every day. We follow certain patterns and bring you break out alerts, volume spikes, breaking news, mergers and upward trends.
This is a sample footer. This text can be customized from the options page. Good luck.